A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases

British Journal of Dermatology

Volumn 167, Issue 4, 2012, Pages 888-900

  Katugampola, R P ^a   Anstey, A V ^a   Finlay, A Y ^a   Whatley, S ^b   Woolf, J ^b   Mason, N ^b   Deybach, J C ^c,d   Puy, H ^c,d   Ged, C ^e   De Verneuil, H ^e   Hanneken, S ^f   Minder, E ^g   Schneider Yin, X ^g   Badminton, M N ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^d HÔPITAL LOUIS MOURIER   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^g Institute of Laboratory Medicine   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ARTIFICIAL TEAR; BETA CAROTENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CHARCOAL; COLESTYRAMINE; ERYTHROPOIETIN; FLUORIDE SODIUM; LUBRICATING AGENT; MOUTHWASH; SUNSCREEN; VITAMIN D;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BLEPHARITIS; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC WOUND; CLINICAL ARTICLE; CONGENITAL ERYTHROPOIETIC PORPHYRIA; CONSERVATIVE TREATMENT; CORNEA TRANSPLANTATION; CORNEA ULCER; DENTAL CARIES; DISEASE SEVERITY; DRUG WITHDRAWAL; DRY EYE; ECTROPION; ERYTHROPOIESIS; ESTHETIC SURGERY; EYE SURGERY; FEMALE; FRANCE; GENOTYPE PHENOTYPE CORRELATION; GERMANY; HEMOLYTIC ANEMIA; HUMAN; HYPERTRICHOSIS; LEUKOPENIA; LONG TERM CARE; MALE; OINTMENT; ONSET AGE; OSTEOPOROSIS; PHOTOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROTECTIVE CLOTHING; QUALITY OF LIFE; RADIATION PROTECTION; SCHOOL CHILD; SCLERITIS; SPLENECTOMY; SUNLIGHT PROTECTION; SWITZERLAND; THROMBOCYTOPENIA; TOOTH DISCOLORATION; TOOTH DISEASE; TOOTH EXTRACTION; TREATMENT DURATION; TREATMENT OUTCOME; ULTRAVIOLET RADIATION; UNITED KINGDOM; VITAMIN D DEFICIENCY; WOUND CARE;

ADOLESCENT; ADULT; ALGORITHMS; BETA CAROTENE; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CHARCOAL; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; EUROPE; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PORPHYRIA, ERYTHROPOIETIC; PROTECTIVE CLOTHING; SEVERITY OF ILLNESS INDEX; SPLENECTOMY; YOUNG ADULT;

EID: 84867009096     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11154.x     Document Type: Article

References (41)

1. Anderson K, Sassa S, Bishop D, et al. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: The Metabolic & Molecular Basis of Inherited Disease (, Scriver CR, Beasdet AL, Sly WS, Valle D, eds), 8th edn. New York: McGraw-Hill Publishing, 2001; 2991-3062.
2. Desnick RJ, Astrin KH,. Congenital erythropoietic porphyria: advances in pathogenesis and treatment. Br J Haematol 2002; 117: 779-95.
3. De Verneuil H, Ged C, Moreau-Gaudry F,. Congenital erythropoietic porphyria. In: The Porphyrin Handbook (, Kadish K, Smith K, Guilard R, eds), 2nd edn. New York, NY: Elsevier Science, 2003; 43-65.
4. Fritsch C, Bolsen K, Ruzicka T, et al. Congenital erythropoietic porphyria. J Am Acad Dermatol 1997; 36: 594-610.
5. Katugampola RP,. Assessment of clinical and laboratory data to inform management decisions in congenital erythropoietic porphyria. MD thesis, Cardiff University, U.K., 2010.
6. Haining RG, Cowger ML, Labbe RF, Finch CA,. Congenital erythropoietic porphyria. II. The effect of induced polycythemia. Blood 1970; 36: 297-309.
7. Piomelli S, Poh-Fitzpatrick MB, Seaman C, et al. Complete suppression of the symptoms of congenital erythropoietic porphyria by long-term treatment with high-level transfusions. N Engl J Med 1986; 314: 1029-31.
8. Pimpstone N, Gandhi S, Mukerji S,. Therapeutic efficacy of oral charcoal in congenital erythropoietic porphyria. N Engl J Med 1987; 316: 390-3.
9. Gorchein A, Guo R, Lim CK, et al. Porphyrins in urine, plasma, erythrocytes, bile and faeces in a case of congenital erythropoietic porphyria (Gunther's disease) treated with blood transfusion and iron chelation: lack of benefit from oral charcoal. Biomed Chromatogr 1998; 12: 350-6.
10. Aldrich RA, Hawkinson V, Grinstein M, Watson CJ,. Photosensitive or congenital porphyria with haemolytic anaemia. I. Clinical and fundamental studies before and after splenectomy. Blood 1951; 6: 685-98.
11. Kauffman L, Evans D, Stevens R, Weinkove C,. Bone-marrow transplantation for congenital erythropoietic porphyria. Lancet 1991; 337: 1510-11.
12. Zix-Kieffer I, Langer B, Eyer D, et al. Successful cord blood stem cell transplantation for congenital erythropoietic porphyria (Gunther's disease). Bone Marrow Transplant 1996; 18: 217-20.
13. Thomas C, Ged C, Nordmann Y, et al. Correction of congenital erythropoietic porphyria by bone marrow transplantation. J Pediatr 1996; 129: 453-6.
14. Lagarde C, Hamel-Teillac D, De Prost Y, et al. Allogreffe de moelle osseuse dans la porphyrie erythropoietique congenitale. Ann Dermatol Venereol 1998; 125: 114-17 [Article in French].
15. Tezcan I, Xu W, Gurgey M, et al. Congenital erythropoietic porphyria successfully treated by allogeneic bone marrow transplantation. Blood 1998; 92: 4053-8.
16. Fritsch C, Land K, Bolsen K, et al. Congenital erythropoietic porphyria. Skin Pharmacol Appl Skin Physiol 1998; 11: 347-57.
17. Shaw PH, Mancini AJ, McConnell JP, et al. Treatment of congenital erythropoietic porphyria in children by allogeneic stem cell transplantation: a case report and review of the literature. Bone Marrow Transplant 2001; 27: 101-5.
18. Harada F, Shwayder T, Desnick RJ, et al. Treatment of severe congenital erythropoietic porphyria by bone marrow transplantation. J Am Acad Dermatol 2001; 45: 279-82.
19. Dupuis-Girod S, Akkari V, Ged C, et al. Successful matched-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (Günther disease). Eur J Pediatr 2005; 164: 104-7.
20. Phillips J, Steensma D, Pulsipher M, et al. Congenital erythropoietic porphyria due to a mutation in GATA-1: the first trans-acting mutation causative for a human porphyria. Blood 2007; 109: 2618-21.
21. Taibjee S, Stevenson O, Abdullah A, et al. Allogeneic bone marrow transplantation in a 7-year-old girl with congenital erythropoietic porphyria: a treatment dilemma. Br J Dermatol 2007; 156: 567-71.
22. Faraci M, Morreale G, Boeri E, et al. Unrelated HSCT in an adolescent affected by congenital erythropoietic porphyria. Pediatr Transplant 2008; 12: 117-20.
23. Lebreuilly-Sohyer I, Morice A, Acher A, et al. Congenital erythropoietic porphyria treated by haematopoietic stem cell allograft. Ann Dermatol Venereol 2010; 137: 635-9 [Article in French].
24. Hogeling M, Nakano T, Dvorak CC, et al. Severe neonatal congenital erythropoietic porphyria. Pediatr Dermatol 2011; 28: 416-20.
25. Singh S, Khanna N, Kumar L,. Bone marrow transplantation improves symptoms of congenital erythropoietic porphyria even when done post puberty. Indian J Dermatol Venereol Leprol 2012; 78: 108-11.
26. Katugampola RP, Badminton MN, Finlay AY, et al. Congenital erythropoietic porphyria: a single-observer clinical study of 29 cases. Br J Dermatol 2012; in press. DOI: 10.1111/j.1365-2133.2012.11154.
27. Katugampola RP, Lake A,. The role of photography in dermatology research. J Vis Commun Med 2012; 35: 5-10.
28. Badminton M, Elder G,. Management of acute and cutaneous porphyrias. Int J Clin Pract 2002; 56: 272-8.
29. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
30. Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005; 125: 659-64.
31. Fayle SA, Pollard MA,. Congenital erythropoietic porphyria-oral manifestations and dental treatment in childhood: a case report. Quintessence Int 1994; 25: 551-4.
32. Pullon H, Bellingham A, Humphreys S, et al. The osteodystrophy of congenital erythropoietic porphyria. Bone 1991; 12: 89-92.
33. Lewis-Jones M, Finlay A,. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132: 942-9.
34. Basra M, Sue-Ho R, Finlay AY,. The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease. Br J Dermatol 2007; 156: 528-38.
35. Small P, Dickson R,. The radiological features of congenital porphyria. Br J Radiol 1970; 43: 732-4.
36. Ged C, Moreau-Gaudry F, Richard E, et al. Congenital erythropoietic porphyria: mutation update and correlation between genotype and phenotype. Cell Mod Biol (Noisy-le-grand) 2009; 55: 53-60.
37. Moss C, Wong A, Davies P,. The Birmingham Epidermolysis Bullosa Severity Score: development and validation. Br J Dermatol 2009; 160: 1057-65.
38. Moreau-Gaudry F, Ged C, de Verneuil H,. Gene therapy for erythropoietic porphyria. Gene Ther 1996; 3: 843-4.
39. Robert-Richard E, Moreau-Gaudry F, Lalanne M, et al. Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells. Am J Hum Genet 2008; 82: 113-24.
40. European Porphyria Network. Congenital erythropoietic porphyria (CEP). Available at: http://www.porphyria-europe.com/01-for-patients/EN/Congenital- Erythropoietic-Porphyria.asp (last accessed 24 July 2012).
41. British Association of Dermatologists. Congenital erythropoietic porphyria. Patient Information Leaflet. Available at: http://www.bad.org.uk// site/1274/default.aspx (last accessed 24 July 2012).